Friday, 29 June 2012

NanoIVD - Product Pipeline Analysis

NanoIVD, Inc. (Nano) is a medical device company based in the US. The company researches, develops, and commercializes blood-based tests for cancer-recurrence monitoring, treatment-effectiveness monitoring, and personalized molecular cancer profiling for therapeutic selection. It also owns an algorithm for cancer biomarker selection and proprietary nanowire field-effect-transistor (NW-FET) chip technology for label-free and real-time diagnostic testing. Nano’s biosensor chip is embedded in a disposable test cartridge, and can detect pico and femto grams per milliliter of proteins and nucleic acids in less than 15 minutes. The company is partnered with the companies such as, Cedars Sinai Medical Center, Beverly Hills Cancer Center, California NanoSystems Institute, Electrical Engineering and Kavli Nanoscience Institute. Nano is headquartered in Los Angeles, California, the US.

This report is a source for data, analysis and actionable intelligence on the NanoIVD portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date.

Each pipeline product is profiled to cover information on product description, function, technology, indication, and application. The report is also supplemented with a detailed company profile and information on clinical trials, wherever applicable.

Scope

- Detailed NanoIVD company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments.
- Detailed coverage on all the NanoIVD pipeline products, by equipment type, by therapy area, by development stage, and by trial phase.
- Information on product milestones and pipeline territory for each product, the estimated approval date, and estimated launch date.
- Profile of each pipeline product with additional information on product description, function, technology, indication(s), and application.
- Data on relevant NanoIVD clinical trials and product patent details, wherever applicable.
- Information on clinical trial, wherever applicable, is supplemented with information on trial phase, trial status, trial objective, trial design, target patients, unique physician identifier, primary point, secondary point, acronym, participants inclusion, participants exclusion, interventions, trial results, trial start date, trial end date, study type, trial site, trial funding, age eligibility, and gender eligibility.

Reasons to Buy

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape globally.
- Design and develop your product development, marketing and sales strategies.
- Exploit M&A opportunities by identifying market players with the most innovative pipeline.
- Develop market-entry and market expansion strategies.
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Develop competition strategies by identifying the status and likely launch of your competitors’ pipeline products through review of the clinical trials, stage and phase of development, etc.
- Which are the next high-value products that your competitor would add in its portfolio? – identify, understand and capitalize.

To view the detailed table of contents for this report please visit: http://www.reportstack.com/product/84625/nanoivd-inc-product-pipeline-analysis.html

Biotrin International - Product Pipeline Analysis

Biotrin International (Biotrin) is a medical device company, based in Ireland. The company provides novel and proprietary tests for the clinician and research scientist. It operates through product segments such as Parvovirus B19, Herpes Virus, Respiratory Virus, Hantavirus and Approved by FDA. Biotrin operates through business units includes infectious disease unit and biomarkers unit. Infectious disease unit provides test for the detection of emerging viral diseases. Biomarkers unit provide test to assess organ and tissue damage. The company distributes its products in Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Cyprus, Czech Republic, Denmark, Egypt, Estonia and the US among others. Biotrin is headquartered in Dublin, Ireland.

This report is a source for data, analysis and actionable intelligence on the Biotrin International portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date.

Each pipeline product is profiled to cover information on product description, function, technology, indication, and application. The report is also supplemented with a detailed company profile and information on clinical trials, wherever applicable.

Scope

- Detailed Biotrin International company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments.
- Detailed coverage on all the Biotrin International pipeline products, by equipment type, by therapy area, by development stage, and by trial phase.
- Information on product milestones and pipeline territory for each product, the estimated approval date, and estimated launch date.
- Profile of each pipeline product with additional information on product description, function, technology, indication(s), and application.
- Data on relevant Biotrin International clinical trials and product patent details, wherever applicable.
- Information on clinical trial, wherever applicable, is supplemented with information on trial phase, trial status, trial objective, trial design, target patients, unique physician identifier, primary point, secondary point, acronym, participants inclusion, participants exclusion, interventions, trial results, trial start date, trial end date, study type, trial site, trial funding, age eligibility, and gender eligibility.

Reasons to Buy

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape globally.
- Design and develop your product development, marketing and sales strategies.
- Exploit M&A opportunities by identifying market players with the most innovative pipeline.
- Develop market-entry and market expansion strategies.
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Develop competition strategies by identifying the status and likely launch of your competitors’ pipeline products through review of the clinical trials, stage and phase of development, etc.
- Which are the next high-value products that your competitor would add in its portfolio? – identify, understand and capitalize.

To view the detailed table of contents for this report please visit: http://www.reportstack.com/product/84622/biotrin-international-product-pipeline-analysis.html

Axela - Product Pipeline Analysis

Axela Inc. (Axela) is medical equipment company, based in Canada. It develops products for protein detection, characterization and monitoring products used in clinical research, health research and life science. Its products include dotLab mX system, panelPlus products, dot-Avidin products, dot-Rready products, dot-Covalent products and spare parts. The company provides services such as, technical and application support, on-site and in-house training, extended warranty, service and maintenance contracts, and custom application development services. It enables the real-time detection and quantization of protein binding events in complex media. The company operates though its distributors in the US and Canada with a European Sales office in Netherlands. The company distributes its products through its brands, dotLab mX, panelPlus, dot-Avidin, dot-Ready and dot-Covalent. Axela is headquartered in Ontario, Canada.

This report is a source for data, analysis and actionable intelligence on the Axela Inc. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date.

Each pipeline product is profiled to cover information on product description, function, technology, indication, and application. The report is also supplemented with a detailed company profile and information on clinical trials, wherever applicable.

Scope

- Detailed Axela company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments.
- Detailed coverage on all the Axela pipeline products, by equipment type, by therapy area, by development stage, and by trial phase.
- Information on product milestones and pipeline territory for each product, the estimated approval date, and estimated launch date.
- Profile of each pipeline product with additional information on product description, function, technology, indication(s), and application.
- Data on relevant Axela clinical trials and product patent details, wherever applicable.
- Information on clinical trial, wherever applicable, is supplemented with information on trial phase, trial status, trial objective, trial design, target patients, unique physician identifier, primary point, secondary point, acronym, participants inclusion, participants exclusion, interventions, trial results, trial start date, trial end date, study type, trial site, trial funding, age eligibility, and gender eligibility.

Reasons to Buy

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape globally.
- Design and develop your product development, marketing and sales strategies.
- Exploit M&A opportunities by identifying market players with the most innovative pipeline.
- Develop market-entry and market expansion strategies.
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Develop competition strategies by identifying the status and likely launch of your competitors’ pipeline products through review of the clinical trials, stage and phase of development, etc.
- Which are the next high-value products that your competitor would add in its portfolio? – identify, understand and capitalize.

To view the detailed table of contents for this report please visit: http://www.reportstack.com/product/84619/axela-inc-product-pipeline-analysis.html

Vascular Closure Systems - Product Pipeline Analysis

Vascular Closure Systems, Inc (VCS) is a medical device company, based in the US. The company develops and commercializes vascular access closure technology for the interventional cardiology market. It develops its medical device based on the intellectual property provided by the CardioVascular Technologies, Inc. Its Intellectual Property (IP) covers more than four different types of sealing methods such as bioabsorbable plug, RF thermal closure, bioabsorbable tubular plug, and self-closing nitinol clip. The Company has entered into an agreement for licensing, manufacturing and distribution of its products in Australia, India, Japan, Philippines, Korea, Malaysia, China, New Zealand, Thailand Singapore, and Taiwan. VCS is headquartered in Livermore, California, the US.

This report is a source for data, analysis and actionable intelligence on the Vascular Closure Systems portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date.

Each pipeline product is profiled to cover information on product description, function, technology, indication, and application. The report is also supplemented with a detailed company profile and information on clinical trials, wherever applicable.

Scope

- Detailed Vascular Closure Systems company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments.
- Detailed coverage on all the Vascular Closure Systems pipeline products, by equipment type, by therapy area, by development stage, and by trial phase.
- Information on product milestones and pipeline territory for each product, the estimated approval date, and estimated launch date.
- Profile of each pipeline product with additional information on product description, function, technology, indication(s), and application.
- Data on relevant Vascular Closure Systems clinical trials and product patent details, wherever applicable.
- Information on clinical trial, wherever applicable, is supplemented with information on trial phase, trial status, trial objective, trial design, target patients, unique physician identifier, primary point, secondary point, acronym, participants inclusion, participants exclusion, interventions, trial results, trial start date, trial end date, study type, trial site, trial funding, age eligibility, and gender eligibility.

Reasons to Buy

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape globally.
- Design and develop your product development, marketing and sales strategies.
- Exploit M&A opportunities by identifying market players with the most innovative pipeline.
- Develop market-entry and market expansion strategies.
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Develop competition strategies by identifying the status and likely launch of your competitors’ pipeline products through review of the clinical trials, stage and phase of development, etc.
- Which are the next high-value products that your competitor would add in its portfolio? – identify, understand and capitalize.

To view the detailed table of contents for this report please visit: http://www.reportstack.com/product/84616/vascular-closure-systems-inc-product-pipeline-analysis.html

Thursday, 28 June 2012

Aperion Biologics - Product Pipeline Analysis

Aperion Biologics Corporation (Aperion Biologics) is a medical device company, based in the US. The company has developed and patented a technique to make animal-tissues usable for human applications without causing rejection. It develops and commercializes tissue engineered products for surgical reconstruction of joints and soft tissue. The company’s products include ligament reconstruction instruments based upon bone patellar tendon bone construct, soft tissue tendon construct, and bone tendon construct. Its products support treatment of orthopedic ligaments, bone, cartilage, meniscus, cardiovascular valves/vessels, and soft tissue augmentation/repair applications, as they used to humanize and sterilize animal tissues. The company has 25 issued patents. Aperion Biologics is headquartered in San Antonio, Texas, the US.

This report is a source for data, analysis and actionable intelligence on the Aperion Biologics portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date.

Each pipeline product is profiled to cover information on product description, function, technology, indication, and application. The report is also supplemented with a detailed company profile and information on clinical trials, wherever applicable.

Scope

- Detailed Aperion Biologics company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments.
- Detailed coverage on all the Aperion Biologics pipeline products, by equipment type, by therapy area, by development stage, and by trial phase.
- Information on product milestones and pipeline territory for each product, the estimated approval date, and estimated launch date.
- Profile of each pipeline product with additional information on product description, function, technology, indication(s), and application.
- Data on relevant Aperion Biologics clinical trials and product patent details, wherever applicable.
- Information on clinical trial, wherever applicable, is supplemented with information on trial phase, trial status, trial objective, trial design, target patients, unique physician identifier, primary point, secondary point, acronym, participants inclusion, participants exclusion, interventions, trial results, trial start date, trial end date, study type, trial site, trial funding, age eligibility, and gender eligibility.

Reasons to Buy

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape globally.
- Design and develop your product development, marketing and sales strategies.
- Exploit M&A opportunities by identifying market players with the most innovative pipeline.
- Develop market-entry and market expansion strategies.
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Develop competition strategies by identifying the status and likely launch of your competitors’ pipeline products through review of the clinical trials, stage and phase of development, etc.
- Which are the next high-value products that your competitor would add in its portfolio? – identify, understand and capitalize.

To view the detailed table of contents for this report please visit: http://www.reportstack.com/product/84584/aperion-biologics-corporation-product-pipeline-analysis.html

Rayner Intraocular Lenses - Product Pipeline Analysis

Rayner Intraocular Lenses Limited (Rayner) is a medical device company, based in the UK. The company manufactures intra ocular lens (IOL). Its products include Sulcoflex which includes Sulcoflex Aspheric, Sulcoflex Toric and Sulcoflex Multifocal; Multifocal which includes M-flex, M-flex T and Sulcoflex multifocul; Toric which includes T-flex, M-flex T and Sulcoflex toric; Spherical which includes C-flex and Superflex; Aspheric which includes C-flex, Superflex and Sulcoflex; PMMA Intraocular Lenses. It also provides web based toric calculator and ordering system namely Raytrace. The company operates as a subsidiary of Rayner & Keeler Ltd. Rayner is headquartered in East Sussex, the UK.

This report is a source for data, analysis and actionable intelligence on the Rayner Intraocular Lenses portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date.

Each pipeline product is profiled to cover information on product description, function, technology, indication, and application. The report is also supplemented with a detailed company profile and information on clinical trials, wherever applicable.

Scope

- Detailed Rayner Intraocular Lenses company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments.
- Detailed coverage on all Rayner Intraocular Lenses the pipeline products, by equipment type, by therapy area, by development stage, and by trial phase.
- Information on product milestones and pipeline territory for each product, the estimated approval date, and estimated launch date.
- Profile of each pipeline product with additional information on product description, function, technology, indication(s), and application.
- Data on relevant Rayner Intraocular Lenses clinical trials and product patent details, wherever applicable.
- Information on clinical trial, wherever applicable, is supplemented with information on trial phase, trial status, trial objective, trial design, target patients, unique physician identifier, primary point, secondary point, acronym, participants inclusion, participants exclusion, interventions, trial results, trial start date, trial end date, study type, trial site, trial funding, age eligibility, and gender eligibility.

Reasons to Buy

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape globally.
- Design and develop your product development, marketing and sales strategies.
- Exploit M&A opportunities by identifying market players with the most innovative pipeline.
- Develop market-entry and market expansion strategies.
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Develop competition strategies by identifying the status and likely launch of your competitors’ pipeline products through review of the clinical trials, stage and phase of development, etc.
- Which are the next high-value products that your competitor would add in its portfolio? – identify, understand and capitalize.

To view the detailed table of contents for this report please visit: http://www.reportstack.com/product/84580/rayner-intraocular-lenses-limited-product-pipeline-analysis.html

Innocoll Technologies - Product Pipeline Analysis

Innocoll Technologies Ltd (Innocoll Technologies) is a medical device company, based in Ireland. The company develops and markets drug delivery devices for the pharmaceutical and medical markets. Its product pipeline includes cogenzia, xaracoll, gentamicin surgical implant, procoll, durieva. The company’s approve products include gentamicin surgical implant, collaguard adhesion barrier, zorprevasurgical haemostat, collacare family, collexa, lidocoll, innocoll dental. Its products are developed using its technologies namely CollaRx and Liquicoll. Innocoll Technologies products are used in a variety of medical applications such as preventing surgical adhesions in the treatment of post-operative or post-traumatic pain or inflammation and treating deep wounds such as ulcers, burns and acute trauma injuries. Its partners include Baxter, EUSA pharma, Merus labs, curesys, KMA, Pioneer Pharma. Innocoll Technologies is headquartered in Roscommon, Ireland.

This report is a source for data, analysis and actionable intelligence on the Innocoll Technologies portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date.

Each pipeline product is profiled to cover information on product description, function, technology, indication, and application. The report is also supplemented with a detailed company profile and information on clinical trials, wherever applicable.

Scope

- Detailed Innocoll Technologies company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments.
- Detailed coverage on all the Innocoll Technologies pipeline products, by equipment type, by therapy area, by development stage, and by trial phase.
- Information on product milestones and pipeline territory for each product, the estimated approval date, and estimated launch date.
- Profile of each pipeline product with additional information on product description, function, technology, indication(s), and application.
- Data on relevant Innocoll Technologies clinical trials and product patent details, wherever applicable.
- Information on clinical trial, wherever applicable, is supplemented with information on trial phase, trial status, trial objective, trial design, target patients, unique physician identifier, primary point, secondary point, acronym, participants inclusion, participants exclusion, interventions, trial results, trial start date, trial end date, study type, trial site, trial funding, age eligibility, and gender eligibility.

Reasons to Buy

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape globally.
- Design and develop your product development, marketing and sales strategies.
- Exploit M&A opportunities by identifying market players with the most innovative pipeline.
- Develop market-entry and market expansion strategies.
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Develop competition strategies by identifying the status and likely launch of your competitors’ pipeline products through review of the clinical trials, stage and phase of development, etc.
- Which are the next high-value products that your competitor would add in its portfolio? – identify, understand and capitalize.

To view the detailed table of contents for this report please visit: http://www.reportstack.com/product/84578/innocoll-technologies-ltd-product-pipeline-analysis.html